Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

14.07 +0.67 (+5.04%)

Streaming Delayed Price Updated: 12:29 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress ↗

November 06, 2025

REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026.

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Analyst Expectations For Regenxbio's Future ↗

August 19, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

What to Expect from Regenxbio's Earnings ↗

May 09, 2025

Via Benzinga

The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts ↗

October 07, 2025

Via Benzinga

7 Analysts Assess Regenxbio: What You Need To Know ↗

October 07, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts ↗

September 08, 2025

Via Benzinga

Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date ↗

September 05, 2025

Regenxbio reported sustained biomarker reduction and positive neurodevelopmental outcomes in the pivotal CAMPSIITE trial of RGX-121 for MPS II.

Via Benzinga

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year ↗

August 19, 2025

FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients.

Via Benzinga

REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls ↗

August 07, 2025

REGENXBIO Q2 2025 earnings miss estimates with $21.36M revenue and -$1.38 EPS. Stock drops 2.3% pre-market amid clinical pipeline updates for DMD and diabetic retinopathy therapies.

Via Chartmill

Topics Earnings

Navigating the Currents: Top Sectors Primed for Growth in Q3 2025

August 27, 2025

The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,...

Via MarketMinute

Topics Artificial Intelligence Economy Retirement

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts ↗

June 09, 2025

Via Benzinga

Crude Oil Moves Higher; Ciena Posts Downbeat Earnings ↗

June 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 05, 2025

Via Benzinga

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer ↗

June 05, 2025

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Via Benzinga

Dow Dips Over 100 Points; US Jobless Claims Increase ↗

June 05, 2025

Via Benzinga

Topics Stocks

Which stocks are gapping on Thursday? ↗

June 05, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

The One-Minute Market Report - Saturday, April 26 ↗

April 26, 2025

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, ETFs, and stocks that moved the market higher, as well as the market segments that defied the...

Via Talk Markets

Topics ETFs Stocks / Equities

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

What's going on in today's after hours session ↗

March 31, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

March 26, 2025

Via Benzinga

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial ↗

March 19, 2025

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.

Via Benzinga

Signet Jewelers, BGM Group, StoneCo, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday ↗

March 19, 2025

Via Benzinga

Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday ↗

March 14, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts ↗

March 14, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.